Christine Lu MSc, PhD is an Assistant Professor in the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute and Co-Director of the PRecisiOn Medicine Translational Research (PROMoTeR) Center. She is a pharmacist, health policy scientist and pharmacoepidemiologist. After receiving an MSc (Biopharmaceuticals) and a PhD in Clinical Pharmacology from the University of New South Wales, Australia, Dr. Lu completed her post-doctoral training at Harvard Medical School. Currently Dr. Lu’s primary research focuses on the policy, legal, ethical, economic and societal issues in precision medicine, which have substantial impacts on the clinical integration of genomic testing and sequencing. She is Co-Principal Investigator of Genomics-based Technologies: Access and Reimbursement Issues. Dr. Lu provides intense one-on-one mentorship to PhD students, post-doctoral students, researchers, and mid-career university faculty. Please direct inquiries about fellowships and training opportunities relating to precision medicine research to Dr. Lu
Dr. Lu has contributed substantially to evaluations of health policies in developing and developed countries using large, longitudinal administrative healthcare data and rigorous quasi-experimental research methods. Dr. Lu led a national investigation of the effects of Food and Drug Administration‘s warnings and media attention regarding antidepressant and suicidality among youth. She received an Early Career Investigator award from the national Health Care Systems Research Network for this work. Dr. Lu is Co-Principal Investigator of a PCORI project (IHS-1408-20393) examining effects of high-deductible insurance plans on patients with bipolar disorder and an investigator of another four major projects assessing the impact of high-deductible insurance on appropriate health care.
Since 2003, Dr. Lu has examined access to high-cost specialty drugs (i.e., biologics for rare and chronic conditions including cancer, rheumatoid arthritis, hepatitis C, and rare diseases). She is the lead investigator of an international study of managed entry agreements for such drugs. Dr. Lu is the lead of a national study examining reimbursement of direct acting antivirals for chronic hepatitis C under state Medicaid programs, and the Principal Investigator of a regional study examining approaches for managing the use of direct acting antivirals for chronic hepatitis C.
Dr. Lu is an investigator of the Cancer Research Network and the Mental Health Research Network, the Health Care Systems Research Network. She also serves as a pharmacoepidemiologist for the FDA-funded Sentinel System, a congressionally mandated national medical product safety surveillance system.